Publications by authors named "Amir Dehsarvi"

In Alzheimer's disease (AD), Aβ triggers p-tau secretion, which drives tau aggregation. Therefore, it is critical to characterize modulators of Aβ-related p-tau increases which may alter AD trajectories. Here, we assessed whether factors known to alter tau levels in AD modulate the association between fibrillar Aβ and secreted p-tau determined in the cerebrospinal fluid (CSF).

View Article and Find Full Text PDF

Background: Preclinical, postmortem, and positron emission tomography (PET) imaging studies have pointed to neuroinflammation as a key pathophysiological hallmark in primary 4-repeat (4R) tauopathies and its role in accelerating disease progression.

Objective: We tested whether microglial activation (1) progresses in similar spatial patterns as the primary pathology tau spreads across interconnected brain regions, and (2) whether the degree of microglial activation parallels tau pathology spreading.

Methods: We examined in vivo associations between tau aggregation and microglial activation in 31 patients with clinically diagnosed 4R tauopathies, using 18F-PI-2620 PET and 18F-GE180 (translocator protein [TSPO]) PET.

View Article and Find Full Text PDF
Article Synopsis
  • Four-repeat tauopathies are brain diseases that happen when a protein called 4R tau builds up in certain areas of the brain, affecting how it works.
  • Two main types of these diseases are progressive supranuclear palsy (PSP) and corticobasal degeneration, which both cause problems in brain regions that are important for movement and other functions.
  • The researchers are trying to figure out how the problems in one part of the brain (subcortical) affect other connected areas (cortical) by studying patients and using special brain scans to see how these changes relate to each other.
View Article and Find Full Text PDF
Article Synopsis
  • - In Alzheimer's disease, amyloid-beta (Aβ) causes tau pathology to spread through the brain, and abnormal synaptic activity contributes to this process.
  • - The study examined 93 patients and found that higher levels of the presynaptic protein GAP-43, which indicates synaptic changes, were linked to quicker tau accumulation related to Aβ.
  • - The results suggest that targeting synapses could be a potential strategy for preventing the spread of tau pathology in Alzheimer's, highlighting the connection between synaptic changes and tau spread.
View Article and Find Full Text PDF

Objective: Chronic fatigue is a major clinical unmet need among patients with rheumatoid arthritis (RA). Current therapies are limited to nonpharmacological interventions, such as personalized exercise programs (PEPs) and cognitive-behavioral approaches (CBAs); however, most patients still continue to report severe fatigue. To inform more effective therapies, we conducted a magnetic resonance imaging (MRI) brain study of PEPs and CBAs, nested within a randomized controlled trial (RCT), to identify their neurobiological mechanisms of fatigue reduction in RA.

View Article and Find Full Text PDF

Importance: For the Alzheimer disease (AD) therapies to effectively attenuate clinical progression, it may be critical to intervene before the onset of amyloid-associated tau spreading, which drives neurodegeneration and cognitive decline. Time points at which amyloid-associated tau spreading accelerates may depend on individual risk factors, such as apolipoprotein E ε4 (ApoE4) carriership, which is linked to faster disease progression; however, the association of ApoE4 with amyloid-related tau spreading is unclear.

Objective: To assess if ApoE4 carriers show accelerated amyloid-related tau spreading and propose amyloid positron emission tomography (PET) thresholds at which tau spreading accelerates in ApoE4 carriers vs noncarriers.

View Article and Find Full Text PDF

With the increase in large multimodal cohorts and high-throughput technologies, the potential for discovering novel biomarkers is no longer limited by data set size. Artificial intelligence (AI) and machine learning approaches have been developed to detect novel biomarkers and interactions in complex data sets. We discuss exemplar uses and evaluate current applications and limitations of AI to discover novel biomarkers.

View Article and Find Full Text PDF

Artificial intelligence (AI) and machine learning (ML) approaches are increasingly being used in dementia research. However, several methodological challenges exist that may limit the insights we can obtain from high-dimensional data and our ability to translate these findings into improved patient outcomes. To improve reproducibility and replicability, researchers should make their well-documented code and modeling pipelines openly available.

View Article and Find Full Text PDF

Introduction: Machine learning (ML) has been extremely successful in identifying key features from high-dimensional datasets and executing complicated tasks with human expert levels of accuracy or greater.

Methods: We summarize and critically evaluate current applications of ML in dementia research and highlight directions for future research.

Results: We present an overview of ML algorithms most frequently used in dementia research and highlight future opportunities for the use of ML in clinical practice, experimental medicine, and clinical trials.

View Article and Find Full Text PDF

Background: Overt sentence reading in mild cognitive impairment (MCI) and mild-tomoderate Alzheimer's disease (AD) has been associated with slowness of speech, characterized by a higher number of pauses, shorter speech units and slower speech rate and attributed to reduced working memory/ attention and language capacity.

Objective: This preliminary case-control study investigates whether the temporal organization of speech is associated with the volume of brain regions involved in overt sentence reading and explores the discriminative ability of temporal speech parameters and standard volumetric MRI measures for the classification of MCI and AD.

Methods: Individuals with MCI, mild-to-moderate AD, and healthy controls (HC) had a structural MRI scan and read aloud sentences varying in cognitive-linguistic demand (length).

View Article and Find Full Text PDF
Article Synopsis
  • Researchers are working on identifying new biomarkers for early Alzheimer's disease detection and predicting the transition from Mild Cognitive Impairment (MCI) to Alzheimer’s.
  • The study examines how speech timing during conversations relates to cognitive function and brain volume reductions in areas affected by MCI and AD.
  • Results show that individuals with MCI and mild-to-moderate AD tend to speak more slowly, which could serve as an indicator for early cognitive decline in clinical and community settings.*
View Article and Find Full Text PDF